Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2007-11-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 242

Registration Number: NCT00190710

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck

Phase 3

Completed

Conditions: Skin Cancer

Interventions: Radiation: Radiotherapy
Drug: Carboplatin

First Posted Date: 2005-09-19

Last Posted Date: 2018-04-06

Lead Sponsor: Trans Tasman Radiation Oncology Group

Target Recruit Count: 321

Registration Number: NCT00193895

Locations: 🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇦🇺
Genesis Cancer Care (previously Premion), Tugun, Queensland, Australia
🇳🇿
Christchurch Hospital, Christchurch, New Zealand

and more 18 locations

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: carboplatin
Drug: melphalan
Drug: cyclophosphamide
Procedure: adjuvant therapy
Drug: thiotepa
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Procedure: bone marrow ablation with stem cell support
Radiation: radiation therapy

First Posted Date: 2005-09-16

Last Posted Date: 2017-02-23

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 32

Registration Number: NCT00182793

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma

Phase 2

Completed

Conditions: Retinal Neoplasms
Retinoblastoma

First Posted Date: 2005-09-16

Last Posted Date: 2020-08-05

Lead Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago

Target Recruit Count: 30

Registration Number: NCT00179920

Locations: 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States

Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma

Phase 2

Completed

Conditions: Brain Stem Neoplasms, Primary
Neoplasms, Brain Stem

First Posted Date: 2005-09-16

Last Posted Date: 2019-02-05

Lead Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago

Target Recruit Count: 47

Registration Number: NCT00179881

Locations: 🇺🇸
Children's Hospitals and Clinics, Saint Paul, Minnesota, United States
🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Washington University Medical Center, Saint Louis, Missouri, United States

and more 2 locations